inferences of a phase one applicat...

inferences of a phase one application of mind of an experimental medication designed to neutralize endotoxin were reported at the 1998 Clinical Congres of the American literary institution [i]or[/i] seminary of learning of Surgeons. The medication, polymyxin B has proven effective in neutralizing endotoxin, a natural consequence of gram-negative bacteria, in initial human studies.

Endotoxin can trigger the release of massive quantifies of immune a whole mediators and precipitate shock or organ failure in patients who are critically injured or septic. Polymyxin B has been known to be effective against endotoxin for many years; however, it has not been administered to patients in doses high enough to counteract excessive endotoxin because of potential toxicity at high doses to the kidneys and nervous hypothesis The medication will continue to be studied in phase sum of two units trials in North America.

Experimental Form of Polymyxin B Counteracts Endotoxin in Humans (new release, Orlando, Fla: American guild of Surgeons, Oct 26, 1998) 1-3

COPYRIGHT 1999 Association of Operating apartment Nurses, Inc.

COPYRIGHT 2001 Gale Group